Mycotopia Therapies, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TPIA research report →
About the company
Mycotopia Therapies, Inc. specializes in the application of psychedelic compounds to address a range of mental health conditions. The company offers therapeutic interventions for ailments such as post-traumatic stress disorder (PTSD), severe anxiety, depression, and serotonin syndrome, in addition to providing support for palliative care.
- CEO
- Benjamin Kaplan
- IPO
- 2006
- Employees
- 1
- HQ
- Aventura, FL, US
Price Chart
- Market Cap
- $113.83K
- P/E
- -0.09
- P/S
- 0.00
- P/B
- -0.12
- EV/EBITDA
- -1.36
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 50.02%
- ROIC
- 57.31%
- Revenue
- $2.18K · 0.00%
- Net Income
- $-2,215,751 · -19.88%
- EPS
- $0.00 · 100.00%
- Op Income
- $-1,844,673
- FCF YoY
- -76.90%
- 52W High
- $0.18
- 52W Low
- $0.01
- 50D MA
- $0.02
- 200D MA
- $0.03
- Beta
- 2.56
- Avg Volume
- 173.85K
Get TickerSpark's AI analysis on TPIA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our TPIA coverage
Recent articles, reports, and earnings notes.
No research on TPIA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TPIA report →Similar companies
Peers in the same neighborhood.